O T C
PAOG Target CBD Pharma Development In Puerto Rico Could Get Boost From COVID-19

Sandusky, OH – Sep 17, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today highlighted recent increased interest in the resurgence of industry-wide Pharmaceutical research and manufacturing in Puerto Rico. PAOG is currently in discussions in to engage a Contract Research Organization (CRO) in Puerto Rico to advance an Investigational New

PAOG Advances RespRx Research Into International CBD Pharma Research Arena

Sandusky, OH – Sep 15, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced an international research initiative to advance its hemp-derived cannabidiol (CBD) pharmaceutical treatment for Chronic Obstructive Pulmonary Disease (COPD). The COPD treatment, RespRx, is derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled

PAOG New Updates Toward Penetrating $5.8B Cannabis Pharmaceutical Market Coming This Friday

Sandusky, OH – Sep 14, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced an interview of CEO James C. DiPrima on MoneyTV with Donald Baillargeon scheduled for release this Friday, September 18, 2020.  DiPrima will discuss the company’s latest CBD bio pharma developments in addition to fielding questions on

PAOG Rated Bullish And Given PPS Target In Updated Analyst Report Published Today

Sandusky, OH – September 8, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced Goldman Small Cap Research has published an analyst research report update.  PAOG has recently entered the cannabis biopharmaceutical sector through two recent acquisitions.  The company acquired a cannabis cultivation business from Puration, Inc. (PURA). From Kali-Extracts

PAOG Explores Cannabis Respiratory Research Partnership In Israel

Sandusky, OH – August 14, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced the company is aggressively pursuing international research partnerships to advance its cannabis respiratory treatment development. The company recently revealed research partnership developments in Puerto Rico where Congresswoman Jenniffer González Colón and Florida Senator Marco Rubio recently introduced legislation to position Puerto Rico as

PAOG Announces Goldman Small Cap Research Analyst Report

Sandusky, OH – August 13, 2020 –  OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced Goldman Small Cap Research has published an initial analyst report covering PAOG’s outlook following two recent acquisitions moving the company into the cannabis biopharma market sector.  The report highlights that recent acquisitions have repositioned PAOG for

KALY – Kali-Extracts Confirms Acquisition Interest In Its Cannabis Extract Biopharmaceutical Technology

    Dallas, TX – October 24, 2019 — OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed a recent conditional acquisition proposal from an investor interested in the acquisition of KALY’s Cannabis Extract Biopharmaceutical Technology.  KALY CEO Frederick Ferri commented yesterday on the acquisition interest in KALY’s Cannabis

KALY – Kali-Extracts Developing OTC and Prescription CBD Treatments

  Dallas, TX – October 8, 2019 — OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed the company is pursuing the development of Over-The-Counter (OTC) and prescription CBD treatments.  The company yesterday released an update on its latest Cannabis Extract Biopharmaceutical developments.  The information from yesterday’s release to

KALY – Kali Extracts Announces New Website For Its RespRx CBD Formulation To Treat Chronic Obstructive Pulmonary Disease Affecting 65 Million Worldwide

Dallas, TX – Aug 23, 2019 — OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published a new website dedicated to providing information on the company’s recently introduced CBD Formulation, RespRx, for the treatment of Chronic Obstructive Pulmonary Disease (COPD) affecting 65 million people worldwide.  KALY introduced the new

KALY – Kali Extracts Confirms Analyst Report On Cannabis Extract Biopharmaceutical Strategy Scheduled For Publication Next Week

          DALLAS, Aug. 23, 2019–OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed the publication of an analyst report covering the company’s overall cannabis extract biopharmaceutical strategy is scheduled for next week on Wednesday, August 28, 2019. After making a strategic acquisition in Q4 2018

Contact Us

  • 707-OTC-WIRE (707-682-9473)
  • cs@otcprwire.com

All Rights Reserved © 2019